daraxonrasib
Daraxonrasib Emerges as a Promising Contender in Metastatic Pancreatic Cancer
Revolution Medicines unveiled updated clinical results for daraxonrasib in metastatic pancreatic cancer. Early Phase 1 data reveal 47% ORR as monotherapy and 55% in combination with chemotherapy, supporting a pivotal RASolute 303 phase 3 trial in first-line metastatic disease.